[Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Denosumab is a fully human monoclonal antibody, that specifically binds with high affinity to RANK-ligand (RANKL) and prevents interaction of RANKL with its receptor, called RANK (Receptor activator of nuclear factor kappa B). Blocking this signalling pathway (RANKL/RANK pathway) inhibits osteoclast differentiation and activation, and reduces bone resorption. Application of denosumab (60 mg s. c., every six months) results in increased bone mineral density, as showed in several clinical trials. Incidence of new vertebral fractures in postmenopausal women with osteoporosis was reduced significantly by semi-annual application of denosumab versus placebo. Patients suffering from malignant diseases could also benefit from treatment with denosumab in future.